Introduction
Menopausal hormone therapy (MHT) is typically initiated to control climacteric symptoms during early postmenopause. MHT improves quality of life and prevents osteoporotic fracture. 1 However, concerns about risks, including cancers and cardiovascular disease, are still highly prevalent. All-cause mortality (ACM) would be one definite endpoint to use in assessing a complex balance of benefits and risks with MHT. A Cochrane Database of Systematic Reviews (CDSR) study conducted by Boardman et al. 2 The purpose of this study was to propose a scientific and valid position for the conflicting recommendations of the CDSR (2015) 2 and the USPSTF (2017), 10 to rearrange and update the selected articles to include newer publications, and to conduct subgroup analyses by MHT regimen.
Methods and Results
As though adapting an old clinical practice guideline, an adaptive meta-analysis was performed in order to add current evidences and then conduct additional meta-analysis.
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Using citation discovery tools provided by PubMed (https:// www.ncbi.nlm.nih.gov/pubmed/), lists of recent articles 'citing' the articles selected by previous meta-analyses were made. Accordingly, lists of the cited sources in 6 articles by the CDSR 2 and the USPSTF 10 were created and appraised.
As a consequence, the WHI (2012) 12 was used to update the Further, cumulative data, when available, were used, including intervention and post-intervention follow-ups in DOPS, WHI, and ESPRIT, which could provide more robust evidence. The USPSTF used WHI data during the intervention phase only. Interestingly, the protective effect of MHT seemed to be stronger during intervention periods.
ET decreased the ACM significantly in postmenopausal women younger than 60 years. However, EPT did not show statistical significance, even though sHR showed a protective tendency. In the EPT subgroup, the weight of the WHI trial was very high (91.3%). Medroxyprogesterone acetate was used in the WHI trial, and the reduction in ACM seemed to be quite attenuated in the cumulative follow-up compared with the intervention phase. 12 Of note, the norethindrone acetate used in the DOPS trial showed a similar HR during both the intervention phase and in the cumulative data.
